Introduction
============

COPD is a chronic respiratory disorder that currently represents a major public health concern worldwide.[@b1-copd-13-487] It is a major cause of morbidity and mortality at international level, and it has been identified as the third leading cause of death globally.[@b2-copd-13-487],[@b3-copd-13-487] The hallmark of COPD is the presence of airflow obstruction that is not fully reversible, and spirometry is essential for the definite diagnosis of the disease.[@b4-copd-13-487]

Respiratory symptoms -- such as cough, sputum production, and dyspnea -- may precede the development of airflow limitation by many years; yet significant airflow obstruction may develop without symptoms.[@b5-copd-13-487] Estimates of global COPD prevalence rates vary widely, most likely because of methodological differences between studies.[@b6-copd-13-487] The prevalence of spirometry-defined COPD in adults was estimated to be 10% based on the international Burden of Obstructive Lung Diseases (BOLD) survey.[@b7-copd-13-487] In Greece, the prevalence of COPD was estimated to range between 3.5% and 18.4%.[@b5-copd-13-487],[@b8-copd-13-487]--[@b10-copd-13-487]

Primary care physicians (PCPs) play a crucial role in detecting and managing COPD, since they manage the vast majority of patients in the early stages of the disease.[@b4-copd-13-487]--[@b6-copd-13-487],[@b8-copd-13-487],[@b11-copd-13-487],[@b12-copd-13-487] However, the diagnosis of COPD by PCPs is not always consistent to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines in daily clinical practice, mainly because of underuse of spirometry in primary health care (PHC) settings.[@b5-copd-13-487],[@b11-copd-13-487],[@b13-copd-13-487]--[@b18-copd-13-487] As a result, COPD is a disease that is largely underestimated and underdiagnosed.[@b5-copd-13-487],[@b11-copd-13-487] In the USA and Europe, the rate of underdiagnosis varies greatly with the highest estimates reaching up to 86%.[@b13-copd-13-487]--[@b15-copd-13-487] Similarly, in Greece, the percentage of undiagnosed COPD patients in the PHC is really high,[@b5-copd-13-487],[@b11-copd-13-487],[@b16-copd-13-487]--[@b18-copd-13-487] with the study of Spyratos et al[@b11-copd-13-487] reporting that 52.6% of COPD cases are undiagnosed. In contrast, overdiagnosis of the disease, a rather common situation in PHC because, again, of nonuse of spirometry or insufficient training of GPs in the interpretation of pulmonary function tests (PFTs), leads to subsequent unnecessary drug overprescription that increases significantly the already high economic burden of disease[@b11-copd-13-487] as shown previously.[@b19-copd-13-487] In particular, PHC is the gateway to the health system and is expected to resolve up to 85% of health demands as well as to offer comprehensive care coordinated with the other levels of health care.[@b20-copd-13-487]

The aims of the present study were to estimate the overall prevalence and severity of COPD as well as the fraction of already diagnosed and treated COPD patients in a smoking population attending PHC settings in Central Greece, to identify differences between newly and previously diagnosed COPD patients, and to evaluate potential overtreatment in primary care COPD patients.

Methods
=======

The study was conducted in 10 randomly selected PHC centers in urban, suburban, and rural areas in Thessaly, Central Greece, during a 7-month period (May 2016--November 2016). All subjects were aged \>40 years, current smokers or exsmokers, resided near a PHC setting, and were willing to participate in a spirometry surveillance program. Exclusion criteria included no smoking history, a history of lower or upper respiratory infection or antibiotic treatment within the last month, an operative procedure or acute myocardial infarction within last 3 months, and inability to perform spirometry. The potentially eligible participants were selected and screened by PCPs (case-finding program). The study was approved by the Ethics Committee of the University Hospital of Larissa, and all subjects provided written informed consent.

Study design
------------

A survey questionnaire was completed for each participant. The questionnaire included questions on smoking status, occupational exposure, chronic respiratory symptoms (cough, sputum, wheezing, and dyspnea), history of respiratory infections, comorbidities, and history of inhaled medication received during the last 3 years. Additionally, clinical COPD questionnaire (CCQ), COPD assessment test (CAT), and modified Medical Research Council (mMRC) dyspnea scale were completed by all participants. The CCQ was used to assess health-related quality of life (HRQoL). CAT was used to measure the impact of COPD on a person's life and mMRC dyspnea scale to quantify how shortness of breath causes disability. Smoking status was categorized in the following two terms: 1) former smokers included adults who have smoked at least 100 cigarettes in their lifetime but who had quit smoking for at least 12 months and 2) current smokers included adults who have smoked 100 cigarettes in their lifetime and currently smoke cigarettes every day (daily) or some days (nondaily). Smoking status for all subjects was measured in pack-years of cigarette smoking (pys).

Spirometry procedure
--------------------

Spirometry test was performed with a dry spirometer (Spirolab, MIR, Rome, Italy) according to American Thoracic Society (ATS) recommendations.[@b21-copd-13-487] Calibration checks were performed every morning, before the beginning of the spirometry program. Spirometry testing was performed by physicians who had undergone a special training program. Forced expiratory maneuvers were repeated until three reproducible acceptable tests were obtained and the best. Forced expiratory volume in 1 second (FEV~1~), forced vital capacity (FVC), and FEV~1~/FVC ratio were recorded. An acceptable maneuver was defined as follows: 1) an explosive start (no hesitation or sigmoid curve) with a back-extrapolation volume \<150 mL, 2) the maneuver was performed with a maximal inspiration and expiration, 3) no glottis closure or cessation of airflow occurred during the maneuver, 4) no coughs (particularly during the first second), inspirations during the trace or evidence of leaks, and 5) the maneuver met the end-of-test criteria (exhaling for ≥6 seconds with \<50 mL being exhaled in the last 2 seconds).[@b22-copd-13-487] A bronchodilator reversibility test with 400 µg of salbutamol was performed in all patients with obstructive spirometry. Obstructive spirometry was defined as an FEV~1~/FVC of \<0.70 in accordance with GOLD guidelines.[@b23-copd-13-487] A positive response to bronchodilators was defined as an increase in the FEV~1~ of 200 mL and 12% from the prebronchodilator value (baseline value).[@b24-copd-13-487]

Fractional exhaled nitric oxide (FeNO) measurement
--------------------------------------------------

FeNO concentration in exhaled breath was also measured for all subjects. The FeNO levels were measured using a nitric oxide analyzer (NoBreath; Bedfont Scientific Ltd, Maidstone, UK). The testing standards for FeNO followed the guidelines recommended by the ATS and the European Respiratory Society.[@b25-copd-13-487]

Diagnosis of COPD
-----------------

After the completion of the study questionnaire, the measurement of FeNO, and spirometry test, all participants were evaluated by respiratory physicians who established the diagnosis of COPD. The presence of COPD was assessed based on medical history, clinical symptoms, and spirometry results. Classification of COPD was based on the postbronchodilator FEV~1~ (%) according to GOLD guidelines (Stage I/mild COPD, FEV~1~ ≥80%; Stage II/moderate COPD, 50%≤ FEV~1~ \<80%; Stage III/severe COPD, 30%≤ FEV~1~ \<50%; Stage IV/very severe COPD, FEV~1~ ≤30% or FEV~1~ \<50% with respiratory failure).[@b23-copd-13-487],[@b26-copd-13-487] Patients with COPD were also allocated into four groups by GOLD (GOLD Groups A, B, C, and D) according to 2016 and 2017 GOLD guidelines.[@b23-copd-13-487],[@b26-copd-13-487] Additionally, for participants with known COPD, an extra questionnaire regarding COPD and exacerbation history was completed. COPD patients were also asked whether they had previously received a chest X-ray (CXR). In terms of the differentiation between COPD and asthma, asthma diagnosis was based on participants' medical history (presence of symptoms from childhood or adolescence and/or seasonal distribution) and the presence of significant reversibility of airway obstruction on spirometry according to GINA guidelines (improvement in the FEV~1~ of \>12% and 200 mL from the baseline spirometry).[@b27-copd-13-487] Patients with asthma were included in the analysis as non-COPD patients.

Statistical analyses
--------------------

Data were analyzed using the statistical program SPSS 22 (IBM Corporation, Armonk, NY, USA). Quantitative variables were presented as mean with standard deviation (SD), and qualitative variables are presented as frequencies with percentages. Chi-square test was used to explore any associations between qualitative variables. To identify differences between two independent groups when the dependent variable was either ordinal or continuous, unpaired *t*-tests or Mann--Whitney *U* tests were used for normally and skewed data, respectively. Differences between more than two unrelated groups were tested by one-way analysis of variance (ANOVA). A result was considered statistically significant when the *P*-value was \<0.05.

Results
=======

Study flowchart is presented in [Figure 1](#f1-copd-13-487){ref-type="fig"}. At baseline, 247 subjects were enrolled and screened, but only 204 subjects fulfilled inclusion criteria. Of the 204 eligible participants, 186 participants performed an acceptable spirometry and were included in the analysis. From the subjects included, 46 individuals presented with a prebronchodilator FEV~1~/FVC ratio of \<0.70. Thirty-three individuals had a postbronchodilator FEV~1~/FVC of \<70% and diagnosed with COPD. The rest of the 13 subjects were either diagnosed with asthma or in cases with a response that improved postbronchodilator FEV~1~/FVC \>70% but did not meet the spirometric and/or clinical criteria for asthma diagnosis, referral for further specialized investigations was recommended[@b26-copd-13-487] (further evaluation of asthma--COPD overlap). This group was included in the analysis as non-COPD patients.

The demographic and clinical characteristics of 186 subjects enrolled into the study are presented in [Table 1](#t1-copd-13-487){ref-type="table"}. Of the 186 subjects, 68.3% of them were males with a mean age of 62.3±12.6 years. At least one comorbid condition was reported in 82% of the sample, with the most common being arterial hypertension (44.6%); 82.3% had at least one respiratory symptom (dyspnea, cough, sputum, and/or wheezing); and 67.2% of all participants reported that they had been medicated with inhalers for different time periods during the last 3 years, with the combination of LABA/inhaled corticosteroid (ICS) being the most prescribed treatment (24.2%).

Of the 186 subjects, 121 (65.1%) subjects were current smokers and 65 (34.9%) subjects were exsmokers. The mean estimated life-time tobacco exposure was 59±48 pys for exsmokers and 45±30 pys for active smokers (*P*=0.142). A male predominance was detected in both groups (81.5% in exsmokers vs 61.2% in active smokers, *P*=0.004). Furthermore, exsmokers were older than active smokers (68.83±12.44 vs 58.83±11.26 years, respectively, *P*\<0.001). Exsmokers reported significant dyspnea (mMRC ≥2) compared to current smokers (30.8 vs 17.4%, respectively, *P*=0.035) with no differences in the prevalence of other respiratory symptoms (cough, sputum, and wheezing). Both groups had a high rate of cardiac comorbidities. However, exsmokers had more cardiac comorbidities as compared to active smokers (81.5 vs 62%, respectively, *P*=0.006), especially suffered from coronary heart disease (75.4 vs 53.7%, *P*=0.007) and arterial hypertension (56.9 vs 38%, *P*=0.013). Exsmokers had lower proFEV~1~ values as compared to current smokers (2,192±958 vs 2,558±750 mL, *P*=0.005), as well as lower FEV~1~/FVC ratio (63.82±22.89 vs 78.04±18.96, *P*=0.027). No differences were detected in FeNO values (*P*=0.228) or reversibility (*P*=0.743) between two groups.

COPD was diagnosed in 33 of the 186 participants providing a COPD prevalence of 17.8% in the study population. COPD group was constituted of 57.6% (19/33) exsmokers and 42.4% (14/33) active smokers. COPD diagnosis was associated with older age (71±10.3 vs 60.5±12.3 years, *P*\<0.001), male predominance (93.9 vs 62.7%, *P*\<0.001), higher CAT (10.5±7.6 vs 6.7±6.9, *P*=0.003), and mMRC scores (*P*=0.002) as well as sputum production (*P*=0.008). Furthermore, the mean FeNO value was significantly higher in the COPD group compared to that in the non-COPD group (11.68±13.76 vs 7.25±7.82 ppb, *P*=0.019). In [Table 2](#t2-copd-13-487){ref-type="table"}, comparisons of demographic and clinical characteristics of COPD vs non-COPD groups are presented.

Newly diagnosed COPD patients represented 42.4% of the COPD group. Newly diagnosed patients were younger (66±10 vs 75±9 years, *P*=0.009), predominantly current smokers (64.3 vs 35.7%, *P*=0.029), presented with lower mMRC scores (mMRC ≥2: 21.4 vs 57.9%, *P*=0.036) compared to the known COPD individuals. Moreover, they had lower total and functional CCQ scores (*P*=0.033 and 0.013, respectively). One of the five (3/14) newly diagnosed COPD groups included asymptomatic smokers, representing 1.6% of the study participants. Known COPD patients represented 57.6% of COPD group (19/33). Comparisons of demographic and clinical characteristics between newly diagnosed and known COPD patients are presented in [Table 3](#t3-copd-13-487){ref-type="table"}.

COPD patients were asked whether they had ever undergone chest imaging by general practitioners (GPs). In known COPD patients, CXRs were previously performed on 60% of them, mainly for ruling out alternative diagnoses and comorbid conditions. Regarding newly diagnosed COPD patients, none of them had ever undergone a spirometry and 40% of them had a CXR previously performed.

Moreover, 93.9% of all COPD individuals reported that they had received inhaled medication over the last 3 years. Notably, 61% of healthy individuals and 85.7% of newly diagnosed patients reported that they had been medicated with inhalers for various time periods under the guidance of GPs. None of them was referred for further diagnostic assessment by a specialist or spirometry testing according to patients' self-reports.

The majority of COPD patients were classified into risk groups A and B. Depending on GOLD system, a rise in the proportion of COPD patients classified in groups A and B was observed (from 75.8% according to 2016 GOLD[@b23-copd-13-487] classification to 84.8% according to the latest established classification[@b26-copd-13-487]) as presented in [Table 3](#t3-copd-13-487){ref-type="table"}. Furthermore, 85.7% of newly diagnosed patients were in the mild-to-moderate stage of disease and were classified into Stages I and II. Similarly, we observed an increasing proportion of early-stage newly diagnosed COPD patients when they were reclassified according to 2017 GOLD system (from 85.7% to 92.8% according to old and new GOLD guidelines,[@b23-copd-13-487],[@b26-copd-13-487] respectively) ([Table 3](#t3-copd-13-487){ref-type="table"}). Moreover, differences in treatment compliance according to GOLD group were observed. Specifically, we found that only 47.4% of known COPD patients received proper medication according to 2016 GOLD guidelines[@b23-copd-13-487] and only 26.3% of known COPD patients received proper medication according to latest treatment guidelines.[@b26-copd-13-487] Overall, 68.4% of known COPD patients were medicated with ICSs and approximately half of them were being inappropriately treated with triple inhaled therapy ([Table 3](#t3-copd-13-487){ref-type="table"}).

To this end, [Table 4](#t4-copd-13-487){ref-type="table"} summarizes demographics and clinical characteristics of all COPD patients according to different GOLD stages (I--IV) and different GOLD groups (A--D). We found that COPD patients in GOLD Stage III/IV had significantly higher total CCQ score than early-stage patients, as expected. Finally, taking into account GOLD grouping according to 2016[@b23-copd-13-487] and 2017[@b26-copd-13-487] GOLD definition, we found that Groups B and D had more dyspnea and higher mMRC, CAT, and total CCQ scores compared to Groups A and C, as also expected ([Table 4](#t4-copd-13-487){ref-type="table"}). It is worth mentioning that none of the subjects was allocated to 2017 GOLD Group C. This is in accordance to 2017 GOLD update,[@b26-copd-13-487] which reported that Group C is consistently the least prevalent group.

Discussion
==========

The prevalence of COPD among smokers aged 40 years or older, attending this surveillance program, was 17.8%. Only one-half of COPD patients had already been diagnosed and treated; thus, underdiagnosis and missed diagnosis of COPD patients are a concern. We found that newly diagnosed COPD patients were of younger age, current smokers, and less symptomatic; the majority appeared to have COPD of mild and moderate airflow limitation. Remarkably, gaps seem to exist in the implementation of evidence-based guidelines for managing COPD in PHC. First, the phenomenon of COPD overdiagnosis followed by overtreatment came into spotlight, since 61.4% of non-COPD subjects were probably misdiagnosed with COPD and medicated without ever performing spirometry to confirm the diagnosis. Furthermore, a great proportion of newly diagnosed COPD patients (85.7%) had been using inhaled medication under PCPs' prescription without ever undergoing spirometry. Finally, more convincingly, we found that only 26.3% of previously known COPD patients were properly medicated according to 2017 GOLD treatment guidelines, while half of them were inappropriately treated with triple inhaled therapy.

Generally, smoking population participated in this PHC spirometry surveillance program viewed mainly the profile of a male current smoker. The male predominance may be explained by the low smoking habit of females in Greece,[@b9-copd-13-487],[@b28-copd-13-487] especially in rural and suburban areas.[@b5-copd-13-487] Gender-related differences do also exist in COPD patients in Greece. A study conducted in Thessaly (Central Greece) reported that females comprised only 12.5% of COPD patients.[@b5-copd-13-487]

In addition, in this study, different clinical profile was detected among current smokers and exsmokers. Current smokers were younger than exsmokers, which is consistent to published data.[@b29-copd-13-487],[@b30-copd-13-487] However, quitters had higher mean estimated life-time tobacco exposure and reported significantly more dyspnea (mMRC ≥2) and cardiac comorbidities, especially coronary heart disease and arterial hypertension, compared to active smokers. There is abundant evidence that respiratory effects and health sequences associated with cigarette smoke increase motivation to quit smoking.[@b31-copd-13-487] Furthermore, it has previously been described that smoking-associated symptoms such as sputum production and dyspnea might not be completely reversible.[@b32-copd-13-487]

Notably, approximately two-thirds (67.2%) of all study participants reported that they had been treated with inhaled medication over the last 3 years -- especially LABA/ICS combination -- without ever undergoing PFTs or further evaluation by a pulmonologist. Spyratos et al[@b11-copd-13-487] consistently documented that GPs prescribe drugs based on patients' symptoms, clinical examination, and smoking history without using spirometry for the confirmation of the respiratory disease. Without COPD determination and proper classification, GPs blindly treat an obstructive pulmonary disease, usually by the prescription of LABA/ICS, in order to "cover" all COPD stages or bronchial asthma.[@b11-copd-13-487] Moreover, our findings are in agreement with those observed in another Greek study, reporting that LABA/ICS combination was the most frequent medication prescribed, followed by LAMA.[@b33-copd-13-487]

Further analysis of various types of drugs used showed that approximately half of the study participants were medicated with inhalers, while the prevalence of COPD in this particular population was 17.8%. Hence, we can speculate that patients may be too often misdiagnosed with COPD and then overtreated. However, we were not able to reliably verify the accuracy of participants' self-reported diagnoses. It is worth mentioning in this context that 55.4% of the current costs for COPD medication were found to be wasted to overdiagnosis and overtreatment in Greece.[@b11-copd-13-487]

In this article, we reported a significant proportion of COPD patients being diagnosed by the implementation of a PHC-based spirometry program. The reported COPD prevalence rate of our study was obviously limited by a small sample size; however, it is comparable to that found in previously published larger studies.[@b5-copd-13-487],[@b9-copd-13-487],[@b11-copd-13-487] In detail, Spyratos et al[@b11-copd-13-487] reported a COPD prevalence of 10.7% in PHC, and Minas et al[@b5-copd-13-487] found a prevalence of 18.4% in PHC settings of Thessaly (Central Greece) -- in a study conducted before the Greek crisis onset (from January 2006 to June 2007), and included 15 PHC centers in Central Greece. Similarly, in the study of Tzanakis et al,[@b9-copd-13-487] COPD prevalence was recorded to be 15.1% in males living in rural areas.

Specifically, we found a remarkable proportion of newly diagnosed patients, yet COPD remains grossly undiagnosed in PHC by GPs. The large proportion of undiagnosed COPD cases in a PHC is a silent scourge.[@b4-copd-13-487],[@b5-copd-13-487],[@b11-copd-13-487],[@b16-copd-13-487] Herein, however, the rate of newly diagnosed COPD cases observed was lower than previously reported at PHC level, even though only high-risk smokers were screened. Specifically, two-fifths (42.4%) of COPD patients were classified as newly diagnosed, in comparison with two other studies[@b8-copd-13-487],[@b11-copd-13-487] that reported higher proportions of newly diagnosed COPD patients (69% and 52.6%, respectively).[@b8-copd-13-487],[@b11-copd-13-487] Crucially, in support of our strategy, offering spirometry to subjects with tobacco/occupational exposure and at least one respiratory symptom was found to be a very effective screening strategy as more than one-third of participants with airway obstruction could be detected.[@b34-copd-13-487],[@b35-copd-13-487] Other studies indicated that in those with risk factors such as \>20 pack-years of smoking, the diagnostic yield for COPD is relatively high and spirometry should be considered as a method of early case finding.[@b35-copd-13-487],[@b36-copd-13-487] Screening in high-risk smoking groups is also supported by GOLD 2017 guidelines.[@b26-copd-13-487]

Regarding further evaluation of known COPD, we found that CXR is a diagnostic tool for GP, which is mostly used in cases of established COPD. Generally, it has been reported that GPs tend to perform more CXRs than PFTs. Nonetheless, according to established guidelines, CXR is only valuable in excluding alternative diagnoses or identifying significant comorbidities,[@b26-copd-13-487] as it is usually abnormal in patients with severe COPD but may not show changes in up to one-half of patients with mild and moderate COPD.[@b37-copd-13-487],[@b38-copd-13-487]

We documented high proportions of undiagnosed patients with COPD in the early stages of the disease, which is in accordance with previous studies.[@b39-copd-13-487]--[@b41-copd-13-487] Moreover, in our study, we found that newly diagnosed COPD patients were of younger age, current smokers, and presented with fewer symptoms. These findings are consistent with previously published data too.[@b5-copd-13-487]

Although current clinical practice guidelines recommend against screening for COPD in asymptomatic individuals,[@b23-copd-13-487],[@b42-copd-13-487],[@b43-copd-13-487] there are several studies that have revealed a high prevalence of COPD among smokers with minimal or no symptoms.[@b44-copd-13-487] In our study, the group of asymptomatic smokers with COPD represented 1.6% of the study participants and 21% of those who had COPD. These findings are in accordance with a previous study[@b37-copd-13-487] showing that the prevalence of COPD in asymptomatic smokers has been 1.5% when considering the whole group of smokers and 7% when considering the group of nonsymptomatic smokers.[@b44-copd-13-487]

It is well established that COPD is most prevalent in older adults and males with more comorbidities which is also in accordance with our results.[@b24-copd-13-487],[@b45-copd-13-487]--[@b49-copd-13-487] A previous study from our group found that 87.7% of COPD patients report at least one comorbid condition.[@b19-copd-13-487] FeNO levels in COPD are conflictual, but it seems that smoking habits and disease severity are the most important factors influencing FeNO levels in COPD patients.[@b50-copd-13-487],[@b51-copd-13-487] However, we found no significant difference in FeNO levels between ex- and current smokers or between COPD and non-COPD individuals in contradiction to previous studies.[@b50-copd-13-487],[@b51-copd-13-487]

Finally, differences in treatment compliance according to stage of COPD were observed according to 2016 GOLD guidelines,[@b23-copd-13-487] a phenomenon was emphasized more taking into account the most recently published GOLD guidelines.[@b26-copd-13-487] In other words, COPD patients in GOLD Grades A and B were frequently overtreated according to both versions of GOLD guidelines. Analogous results were obtained by Papala et al[@b52-copd-13-487] who identified an overtreatment in all GOLD grades. Spyratos et al[@b11-copd-13-487] also previously reported that only 45% of the subjects were treated according to GOLD guidelines in PHC and 53.1% of the cases were overtreated. As far as corticosteroid use is concerned, we found that approximately half of the known COPD patients were inappropriately treated with triple inhaled therapy. ICS use in early stages of disease was also documented in the study of Tzovaras et al.[@b53-copd-13-487]

Achieving the optimal management of COPD in PHC is a major challenge. Taken together, our findings strongly suggest that GPs usually prescribe treatment without the use of spirometry and/or without taking into account the severity of airway obstruction. The limited access to spirometry in PHC in Greece remains strongly evident.[@b5-copd-13-487] Other causes of COPD misdiagnosis are as follows:[@b54-copd-13-487] 1) due to the threshold of 0.70 used for defining COPD, leading to underdiagnosis in younger patients and overdiagnosis in older patients;[@b54-copd-13-487] 2) errors made in PHC due to GP's lack of awareness of COPD;[@b54-copd-13-487]--[@b59-copd-13-487] 3) errors linked to the spirometry test such as technological errors;[@b54-copd-13-487],[@b59-copd-13-487]--[@b61-copd-13-487] 4) differential diagnoses, which causes diagnostic confusion; and finally 5) patient-related factors such as the absence of obvious respiratory symptoms.[@b54-copd-13-487],[@b62-copd-13-487] Given the underdiagnosis and no refreshment in PHC, both highlighted by our study, in combination with the absence of obvious respiratory symptoms, COPD is often established at a late stage. Thus, symptomatic patients may be referred to a specialist only in severe cases, which is associated with increased COPD disease burden, comorbidities, and costs. Interestingly, it has been reported that opportunities to diagnose COPD earlier are missed for 85% of patients during the 5-year period preceding actual diagnosis.[@b63-copd-13-487] To facilitate implementation of the guidelines, several actions are needed, such as additional resources, further training for professionals, and improved organizational structure for interprofessional collaboration and patient education.[@b64-copd-13-487]

Regarding limited resources, the medical supply short-ages reflect the unfolding humanitarian crisis of the country.[@b65-copd-13-487] A study conducted at the beginning of economic recession revealed major shortages in rural PHC equipment as only 4.6% of rural doctors had spirometers available for clinical use.[@b66-copd-13-487] Consequently, the treatment begins without formal assessment of lung function; the diagnosis is therefore unconfirmed. In fact, spirometry changed the physician's clinical impressions and treatments for approximately one-third of cases.[@b20-copd-13-487],[@b67-copd-13-487]--[@b69-copd-13-487] Another major point is that Greece presents high variability in the distribution of pulmonologists, and therefore, significantly different rates may be observed among regions independently of population risk factors.[@b70-copd-13-487] Many PHCs are located in the remote areas where access to specialists is limited. Patients living in these areas are usually of old age, and transportation is difficult for them; thus, GPs depend on their experience to diagnose COPD.[@b65-copd-13-487],[@b70-copd-13-487]

Moreover, in PHC settings of Greece, there is a lack of training and feedback for diagnostic spirometry by GPs, and both constitute major barriers to its use.[@b11-copd-13-487] Despite numerous guidelines for COPD management, studies conducted both in Greece and globally have consistently shown underutilization of spirometry in COPD diagnosis[@b71-copd-13-487]--[@b75-copd-13-487] and deviations from optimal pharmacological treatment. In other words, gaps exist in the implementation and uptake of evidence-based guidelines for managing COPD in PHC.[@b76-copd-13-487] Providing a theory-driven and evidenced-based COPD intervention is a research and a clinical practice priority. Raising awareness of COPD among PCPs requires a two-pronged approach: education and empowerment.[@b77-copd-13-487] Effective forms of continuing medical education (CME) and questionnaires about the treatment and diagnosis guidelines are important tools to improve guideline adherence and implementation.[@b78-copd-13-487]

Additionally, PCPs play a central role in the multidisciplinary team involved in the diagnosis and treatment of patients with COPD. They play a key role to persuade community members to seek medical care from specialists alerting them to the risk factors and symptoms that they should recognize, in order to seek medical attention at an earlier stage in the disease process.[@b77-copd-13-487]--[@b79-copd-13-487] Better valuing of preventative medicine will help increase the motivation and effectiveness of PHC. Screening and case-finding strategies as well as validated questionnaires in identified cases[@b80-copd-13-487] are the tools in achieving the goal of early diagnosis in COPD.[@b26-copd-13-487]

Access to care and continuity of care are essential for improved quality and greater treatment efficiency to be achieved;[@b81-copd-13-487] however, their implementation in the context of management of major diseases, such as COPD, diabetes mellitus, and coronary heart disease, is a matter of continual scholarly debate. Barriers to health care access emerged as one of the main negative consequences of austerity in Greece, as the proportion of Greek adults who reported unmet health care needs more than doubled in just 5 years, with 12.2% of the respondents citing cost as the main reason for not receiving proper treatment or diagnostic tests.[@b82-copd-13-487]--[@b84-copd-13-487]

Our study presents several limitations. First, the research was limited by a small sample size. Even though we aimed to have a larger sample size, the actual response rate was much lower. The use of a larger sample would improve future studies. Second, a significant limitation of our study lies in the subject selection based on the population attending PHCs. Current smokers and subjects with respiratory symptoms were more likely to attend PHC. Moreover, the enrolled subjects were selected mainly by local GPs; therefore, younger and/or asymptomatic smokers were not easily recruited for the study. These limitations may have influenced the reported prevalence of COPD in our population. Moreover, we aimed mainly at smokers of rural and suburban areas. This may further account for the higher number of male participants, since they represent the vast proportion of smokers in rural and suburban areas of Greece. Therefore, these limitations limit the generalizability of our findings to the general Greek population.

Conclusion
==========

Our study reported a significant prevalence of COPD in 10 PHC settings in Central Greece and emphasized the crucial role of presymptomatic control in PHC. A remarkable proportion of COPD patients were undiagnosed and made case finding worthwhile. The phenomenon of missed diagnosis and overtreatment in certain individuals also came into spotlight. Moreover, appropriate COPD treatment should be a part of current health care agenda. The majority of our findings match perfectly with the global estimations and observations of previous Greek studies, indicating that no refreshment in primary care is a scourge at general practice. Undoubtedly, COPD affects Greeks with significant economic impact, which profoundly deteriorated by persistent errors in COPD management. Higher index of suspicion for the presence of COPD in high-risk smoking groups, wider use of spirometry, and PCPs' CME should be a priority in order to tackle the scourge of COPD in primary care.
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![Flowchart of the study selection process.\
**Notes:** \*Exclusion criteria: no smoking history, a history of lower or upper respiratory infection or antibiotic treatment within the last month, an operative procedure or acute myocardial infarction within the last 3 months, or inability to perform spirometry. Excluded subjects: 17 nonsmokers, five subjects aged \<40 years, 11 subjects with recent respiratory infection, two subjects with recent operative procedure, and eight subjects who did not cooperate with the spirometry procedure.\
**Abbreviation:** PFT, pulmonary function test.](copd-13-487Fig1){#f1-copd-13-487}

###### 

Demographic and clinical characteristics of study participants (N=186)

  Characteristics                                                 Total (n=186)
  --------------------------------------------------------------- ---------------
  Age (years)                                                     62.3±12.6
  Gender                                                          
   Male                                                           127 (68.3)
  BMI (kg/m^2^)                                                   29.1±5.8
  Occupational exposure                                           
   Yes                                                            27 (14.5)
  Area of residence                                               
   Urban                                                          28 (15.1)
   Suburban                                                       59 (31.7)
   Rural                                                          99 (53.2)
  Smoking status                                                  
   Current smoker                                                 121 (65.1)
   Exsmoker                                                       65 (34.9)
   Start smoking age (years)                                      19.7±6.9
   Quit smoking age (years)                                       53.6±13.3
   Pack-years of smoking                                          50±37.8
  Respiratory symptoms                                            
   Cough                                                          92 (49.5)
   Sputum                                                         108 (58.1)
   Wheezing                                                       85 (45.7)
   Dyspnea                                                        105 (56.5)
   mMRC ≥2                                                        41 (22)
   CAT ≥10                                                        57 (30.6)
  Comorbidities                                                   
   Yes                                                            153 (82.3)
   Hypertension                                                   83 (44.6)
   Diabetes                                                       40 (21.5)
   Coronary heart disease                                         22 (11.8)
   Hyperlipidemia                                                 65 (34.9)
  FeNO (ppb)                                                      8±9.2
  ProFEV~1~%                                                      86±21.3
  Inhaled medication[a](#tfn2-copd-13-487){ref-type="table-fn"}   
   No medication                                                  61 (32.8)
   SAMA ± SABA                                                    23 (12.3)
   LAMA or LABA                                                   20 (10.7)
   LAMA/LABA                                                      8 (4.3)
   LABA/ICS                                                       45 (24.2)
   LAMA + LABA/ICS                                                19 (10.2)
   Other medications                                              10 (5.5)

**Notes:** Data are expressed as mean ± standard deviation or as frequency (percentage).

Previously received medication.

**Abbreviations:** BMI, body mass index; CAT, COPD assessment test; FeNO, fractional exhaled nitric oxide; FEV~1~, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; mMRC, modified Medical Research Council; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; SABA, short-acting β2-agonist; SAMA, short-acting muscarinic antagonist.

###### 

Comparisons of COPD and non-COPD groups

  ----------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                                                 Non-COPD group\   COPD group\   *P*-value
                                                                  (n=153)           (n=33)        
  --------------------------------------------------------------- ----------------- ------------- ----------------------------------------------------
  Age (years)                                                     60.5±12.3         71±10.3       \<0.001

  Gender                                                                                          

   Male                                                           96 (62.7)         31 (93.9)     \<0.001

  Occupational exposure                                           25 (16.3)         2 (6.1)       0.128

  Smoking status                                                                                  

   Current smoker                                                 107 (69.9)        14 (42.4)     0.003

   Exsmoker                                                       46 (30.1)         19 (57.6)     0.003

   Start smoking age (years)                                      20.1±7.2          17.9±5.5      0.069[a](#tfn5-copd-13-487){ref-type="table-fn"}

   Quit smoking age (years)                                       50.6±11.2         60.8±15.5     0.003

   Pack-years of smoking                                          45±33             75±48         \<0.001[a](#tfn5-copd-13-487){ref-type="table-fn"}

  Respiratory symptoms                                                                            

   Cough                                                          73 (47.7)         19 (57.6)     0.304

   Sputum                                                         82 (53.6)         26 (78.8)     0.008

   Wheezing                                                       69 (45.1)         16 (48.5)     0.723

   Dyspnea                                                        83 (54.2)         22 (66.7)     0.192

   mMRC ≥2                                                        27 (17.6)         14 (42.4)     0.002

   CAT                                                            6.7±6.9           10.5±7.6      0.003[a](#tfn5-copd-13-487){ref-type="table-fn"}

   CAT ≥10                                                        43 (28)           14 (42)       0.106

   Total CCQ                                                      0.91±0.98         1.68±1.16     \<0.001[a](#tfn5-copd-13-487){ref-type="table-fn"}

  Comorbidities                                                                                   

   Yes                                                            94 (61.4)         26 (81.3)     0.033

   Hypertension                                                   67 (43.8)         16 (48.5)     0.623

   Diabetes                                                       30 (19.6)         10 (30.3)     0.175

   Coronary heart disease                                         17 (11.1)         5 (15.2)      0.514

   Hyperlipidemia                                                 58 (37.9)         7 (21.2)      0.068

  FeNO (ppb)                                                      7.25±7.82         11.68±13.76   0.019[a](#tfn5-copd-13-487){ref-type="table-fn"}

  Pulmonary function test                                                                         

   ProFEV~1~%                                                     76.5±16.6         65.2±22.5     \<0.001

  PostFEV~1~%                                                     90±18.713         68.7±23.6     0.283

   Reversibility (positive response)                              (8.5)             0 (0)         0.083

  Inhaled medication[b](#tfn6-copd-13-487){ref-type="table-fn"}                                   

   Yes                                                            94 (61.4)         31 (93.9)     0.001
  ----------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Data are expressed as mean ± SD or as frequencies (percentages).

Mann-- Whitney *U* test.

Previously received medication.

**Abbreviations:** CAT, COPD assessment test; CCQ, clinical COPD questionnaire; FeNO, fractional exhaled nitric oxide; FEV~1~, forced expiratory volume in 1 second; mMRC, modified Medical Research Council; SD, standard deviation.

###### 

Comparisons of newly diagnosed and known COPD patients

  Characteristics               Newly diagnosed COPD group (n=14)                      Known COPD group (n=19)   *P*-value
  ----------------------------- ------------------------------------------------------ ------------------------- --------------------------------------------------
  Age (years)                   65.7±9.6                                               74.8±9.2                  0.009
  Gender                                                                                                         
   Male                         12 (85.7)                                              19 (100)                  0.089
  Smoking status                                                                                                 
   Current smoker               9 (64.3)                                               5 (26.3)                  0.029
   Exsmoker                     5 (35.7)                                               14 (73.7)                 0.029
   Quit smoking age (years)     50.5±13.2                                              65.2±14.7                 0.049
  Respiratory symptoms                                                                                           
   Cough                        8 (57.1)                                               11 (57.9)                 0.966
   Sputum production            9 (64.3)                                               17 (89.5)                 0.080
   Wheezing                     7 (50.0)                                               9 (47.4)                  0.881
   Dyspnea                      7 (50.0)                                               15 (78.9)                 0.081
   mMRC ≥2                      3 (21.4)                                               11 (57.9)                 0.036
   CAT score                    8±5.9                                                  12.3±8.2                  0.394
   Total CCQ                    1.2±0.8                                                2±1.3                     0.033
   Symptom CCQ                  1.6±1                                                  2.1±1.2                   0.204
   Mental CCQ                   0.7±1                                                  1.5±1.5                   0.073[a](#tfn9-copd-13-487){ref-type="table-fn"}
   Functional CCQ               1.0±0.8                                                2.2±1.7                   0.013
  Vaccination                                                                                                    
   Influenza                    2 (14.3)                                               14 (73.7)                 0.001
   *Streptococcus pneumoniae*   3 (21.4)                                               8 (42.1)                  0.213
  FeNO (ppb)                    7.8±7.7                                                13.5±16.4                 0.646[a](#tfn9-copd-13-487){ref-type="table-fn"}
  GOLD classification                                                                                            
   Stage I                      5 (35.7)                                               3 (15.8)                  0.382
   Stage II                     7 (50)                                                 9 (47.4)                  
   Stage III                    2 (14.3)                                               6 (31.5)                  
   Stage IV                     0                                                      1 (5.3)                   
  GOLD groups 2016                                                                                               
   A                            8 (57.1)                                               6 (31.6)                  0.379
   B                            4 (28.6)                                               7 (36.8)                  
   C                            0                                                      2 (10.5)                  
   D                            2 (14.3)                                               4 (21.1)                  
  GOLD groups 2017                                                                                               
   A                            8 (57.1)                                               8 (42.1)                  0.495
   B                            5 (35.7)                                               7 (36.8)                  
   C                            0                                                      0                         
   D                            1 (7.1)                                                4 (21.1)                  
  Inhaled medication                                                                                             
   No medication                2 (14.3)[b](#tfn10-copd-13-487){ref-type="table-fn"}   0                         0.083
   Only bronchodilators         7 (50.0)[b](#tfn10-copd-13-487){ref-type="table-fn"}   6 (31.6)                  
   Bronchodilators + ICS        5 (35.7)[b](#tfn10-copd-13-487){ref-type="table-fn"}   13 (68.4)                 

**Notes:** Data are expressed as mean ± SD or as frequencies (percentages).

Mann-- Whitney *U* test.

Previously received medication.

**Abbreviations:** CAT, COPD assessment test; CCQ, clinical COPD questionnaire; FeNO, fractional exhaled nitric oxide; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroids; mMRC, modified Medical Research Council; SD, standard deviation.

###### 

Demographics and clinical characteristics of all COPD patients according to different GOLD stages (I--IV) and different 2017 GOLD COPD groups (A--D)

  Characteristics             GOLD stages   2017 GOLD groups[b](#tfn14-copd-13-487){ref-type="table-fn"}                                                                                                                              
  --------------------------- ------------- -------------------------------------------------------------- ---------------------------------------------------- ----------- --------------------------------------------------------- ---------------------------------------------------------
  Age (years)                 73.8±8.2      67.4±11.3                                                      74.8±8.8                                             70.4±12.6   70.9±6.3                                                  72.8±11.9
  Gender                                                                                                                                                                                                                              
   Male                       7 (87.5)      15 (93.8)                                                      9 (100)                                              16 (100)    11 (91.7)                                                 4 (80)
  Smoking status                                                                                                                                                                                                                      
   Current smoker             5 (62.5)      6 (37.5)                                                       3 (33.3)                                             7 (43.8)    5 (41.7)                                                  2 (40)
   Exsmoker                   3 (37.5)      10 (62.5)                                                      6 (66.6)                                             9 (56.2)    7 (58.3)                                                  3 (60)
   Quit smoking age (years)   64±9.2        56.5±18                                                        67.2±11.7                                            57.4±13.6   62.4±16.2                                                 65.5±21
   Pack-years of smoking      80±42.4       62.3±42.9                                                      92.2±58.1                                            79.4±48.2   75±53                                                     59±36.5
  Respiratory symptoms                                                                                                                                                                                                                
   Cough                      6 (75)        8 (50)                                                         5 (55.5)                                             9 (56.2)    8 (66.7)                                                  2 (40)
   Sputum production          6 (75)        12 (75)                                                        8 (88.8)                                             12 (75)     10 (83.3)                                                 4 (80)
   Wheezing                   2 (25)        9 (56.2)                                                       5 (55.5)                                             7 (43.8)    6 (50)                                                    3 (60)
   Dyspnea                    4 (50)        10 (62.5)                                                      8 (88.8)                                             7 (43.8)    10 (83.3)[\*](#tfn15-copd-13-487){ref-type="table-fn"}    5 (100)[\*](#tfn15-copd-13-487){ref-type="table-fn"}
   mMRC ≥2                    4 (50)        5 (31.2)                                                       5 (55.5)                                             0           9 (75)[\*\*](#tfn16-copd-13-487){ref-type="table-fn"}     5 (100)[\*\*](#tfn16-copd-13-487){ref-type="table-fn"}
   CAT score                  11.5±9.4      8.1±6.4                                                        13.9±6.9                                             4.9±3.2     15.1±7.4[\*\*](#tfn16-copd-13-487){ref-type="table-fn"}   17.2±5.1[\*\*](#tfn16-copd-13-487){ref-type="table-fn"}
   Total CCQ                  1.6±1.5       1.2±0.8                                                        2.5±1[\*](#tfn15-copd-13-487){ref-type="table-fn"}   0.9±0.7     2.2±1.2[\*\*](#tfn16-copd-13-487){ref-type="table-fn"}    2.8±0.8[\*\*](#tfn16-copd-13-487){ref-type="table-fn"}
  FeNO (ppb)                  9.9±9         11.9±17.1                                                      13±11.8                                              9.4±7.6     14.8±20.4                                                 11.6±11.5
  Newly diagnosed             5 (62.5)      7 (43.8)                                                       2 (22.2)                                             8 (50)      5 (41.7)                                                  1 (20)

**Notes:** Data are expressed as mean ± SD or as frequencies (percentages).

Stage IV included only one patient.

None of the subjects were allocated to GOLD 2017 group C and reported to be consistently the least prevalent group according to 2017 GOLD update.

A statistically significant difference with a *P*-value of \<0.05.

A statistically significant difference with a *P*-value of \<0.001.

**Abbreviations:** CAT, COPD assessment test; CCQ, clinical COPD questionnaire; FeNO, fractional exhaled nitric oxide; GOLD, Global Initiative for Chronic Obstructive Lung Disease; mMRC, modified Medical Research Council; SD, standard deviation.
